Covid-19 vaccines: In the rush for regulatory approval, do we ...
www.bmj.com › content › 373May 18, 2021 · After rollout under emergency authorisation, manufacturers of covid-19 vaccines now have their sights on regulatory approval. But what’s the rush, asks Peter Doshi , and is just six months of data from now unblinded trials acceptable? In April 2021, Pfizer and Moderna announced efficacy results at the six month mark from the phase III trials of their respective covid-19 vaccines.12 Pfizer ...
Inadvertent subcutaneous injection of COVID-19 vaccine ...
pmj.bmj.com › content › 97/1148/400COVID-19 has been the single greatest public health emergency in the history. The global demand for vaccine vastly outstrip available supply during this scale-up period. There is therefore a need to train up more vaccinators to maximise vaccine uptake in short time period. Like most other vaccines, the COVID-19 vaccine should be given intramuscularly. Muscles have good vascularity, and ...
Covid-19 vaccination: evidence of waning immunity is ...
www.bmj.com › content › 374Sep 23, 2021 · The case for universal boosters is weak, and the benefits are unclear The resurgence of covid-19 in high income countries with advanced vaccine programmes has raised concerns about the durability of vaccine effectiveness, especially against the more transmissible delta variant. This has led some to argue in favour of booster doses for the general population before clear evidence of benefit ...
COVID-19 vaccination and the right to take risks | Journal of ...
jme.bmj.com › content › earlyOct 06, 2021 · The rare but severe cerebral venous thrombosis occurring in some AstraZeneca vaccine recipients has prompted some governments to suspend part of their COVID-19 vaccination programmes. Such suspensions have faced various challenges from both scientific and ethical angles. Most of the criticisms against such suspensions follow a consequentialist approach, arguing that the suspension will lead to ...